Advanced Enzyme reported a significant 33.5% year-on-year increase in net sales for March 2026, reaching INR 116.4 crore. This impressive growth could potentially contribute to the recent fluctuations in the company's stock price.

Vodafone Idea shares have surged, making it an attractive choice for investors. Simultaneously, Tata Consumer Products' strong performance is worthy of consideration. Meanwhile, Rain Industries, Advanced Enzymes, Vijaya Diagnostics, and KIMS are gaining attention as potential buy opportunities.

Advanced Enzyme Technologies attracted attention following its recent earnings report on May 11th. Simultaneously, CMS Info Systems, Oberoi Realty, ABB, and Tata Consumer are currently under the investment community's radar as well.

Advanced Enzyme proposes a final dividend of INR 1.35 per share for the fiscal year 2025-26, pending shareholder approval. Shares touched an intraday high of INR 370.9 on BSE today, indicating strong investor interest.

Advanced Enzyme shares the highlights of their Q4 financial results, offering insights into crucial performance indicators.

Advanced Enzymes is aiming for growth in FY27, focusing on increasing its B2C human nutrition presence in India through a brand called Wellfa. Additionally, the company plans to strengthen its animal nutrition sales teams across the USA, MENA region, and Asia.

Advanced Enzyme's board proposes a final dividend of INR 1.35 per share, pending approval at the company's annual general meeting.

Advanced Enzyme's Q4 EBITDA significantly increased by 38%, reaching approximately $8.6 million, compared to last year. The firm's profit margins also expanded notably, rising to 31.1%.

Today, Blue Dart, Birla Corporation, Gujarat Ambuja Exports, Atlanta Electricals, ASM Tech, Advanced Enzyme, and Sambhv Steel Tubes are set to reveal their Q4 financial results, providing investors with insights into their recent performance.

Advanced Enzyme's Q4 net profit increased significantly by 63%, reaching ₹43 crores, while revenue grew by 9% to ₹203.3 crores. However, the company's EBITDA decreased by 3.8%, and the margin dropped from 35% to 31% year-over-year.

Advanced Enzyme Technologies announced a proposed dividend of INR 1.35 per share for the fiscal year 2025-26, subject to approval at the AGM. The company also reappointed Mr. Mukund Kabra as Whole-Time Director and approved an equity allotment under ESOP, increasing their capital to approximately INR 22.4 crore.

Advanced Enzyme Technologies maintains a strong credit rating, according to CRISIL, with long-term 'A Stable' and short-term 'A1'. A total of Rs. 100 crore in bank loan facilities have been rated, further details can be found on the company's website.

Advanced Enzymes will review its Q4 FY26 financial results during their board meeting on May 9th, 2026. The trading window is closed until May 11th for any potential announcements regarding this matter. For updates, visit the company's official website at advancedenzymes.com.